Bold Capital Partners

Bold Capital Partners investment thesis

We believe some of the most transformative businesses of the next decade will be in health and life sciences. We are particularly interested in investments that reflect the convergence of the physical, digital, virtual, and biological world. Areas of specific focus include longevity, patient-enabled health management, and synthetic biology as it impacts information technology. The intelligent collection and synthesis of data will be a driving force behind advances in those fields. All Health & Life Sciences FILTERS Advanced Manufacturing Applied AI AR/VR Biotechnology Computational Biology Digital Health Drug Discovery Epigenetics Exited Gene Editing Gene Regulation Immunotherapy Microbiome Nanobodies Nanomaterials Networks Robotics Sensors Synthetic Tissue Lining Tissue Engineering Transc

Bold Capital Partners team (11)

Partners and principals at Bold Capital Partners:

• Neal Bhadkamkar — sweet spot $1.5M
• Will Borthwick — sweet spot $1.5M
• Teymour Boutros-Gali — sweet spot $1.5M
• Maxx Bricklin — sweet spot $1.5M
• Peter Diamandis — sweet spot $1.5M
• Emilio Diez Barroso — sweet spot $1.5M
• Pascal Finette — sweet spot $1.5M
• Matt Grob — sweet spot $1.5M
• Neil Jacobstein — sweet spot $1.5M
• Henry Shi — sweet spot $1.5M
• Ysette Witteveen — sweet spot $1.5M

Bold Capital Partners portfolio companies

Companies listed on Bold Capital Partners's public materials include: Investors, Team, Companies, News & Ideas, Careers, Investor Portal, BOLD Longevity Growth, Google Maps, Email us, LinkedIn, Twitter, Hosta AI, Centivax, Near Space Labs, ProRata.ai, Aqtual, Our Companies, All Health & Life Sciences, AliveCor, Bionaut Labs, CareSignal EXIT: M&A, Colossal, Curebase, Deciduous Therapeutics, Deep Longevity EXIT: IPO (SEHK:0575.HK), Discure, Docbot EXIT: M&A, Elevian, Esperto Medical, Evergreen Select, eXo, Feno Labs, Form Bio, Fountain Life, Gallant Pet, Gameto, Holoclara, Human in Motion Robotics, Immunis Biomedical, Insilico Medicine EXIT: IPO (3696.HK), iota Biosciences EXIT: M&A, IVIVA Medical EXIT: M&A, KeyCare, Matrisome Bio, Meru Health, Openwater, OURA Health EXIT: Secondary, Proprio, Seed EXIT: Secondary, SeQureDX EXIT: M&A, Solaria Bio, Stealth Longevity Company, Stuff That Works, Switch Therapeutics, Symbiome, Syntis Bio, Viome, All Deep Tech & Productivity, Akitra, Atomiton.

Is Bold Capital Partners a fit for your round?

Upload your pitch deck and see whether anyone at Bold Capital Partners appears in your top matches.